Webcast ImageWebcast
JMP Securities Life Sciences Conference (Live)
06/19/19 at 12:00 p.m. ET
Webcast ImageWebcast
BMO 2019 Prescriptions for Success Healthcare Conference (Live)
06/25/19 at 11:00 a.m. ET

Corporate Profile

Neos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have three approved ADHD products, two of which use our ODT technology and one of which is an extended-release (ER) oral suspension. Our growing ADHD product portfolio puts Neos in a unique position to help meet the different needs of patients that struggle with ADHD.

News Releases